BriaCell to Present Compelling Data at Leading Cancer Symposium
BriaCell Therapeutics Corp. (NASDAQ: BCTX, BCTXW) and TSX: BCT is gearing up to spotlight its innovative research at the San Antonio Breast Cancer Symposium, one of the most significant gatherings for oncology professionals. The event, taking place in December, will feature five poster presentations, including a standout spotlight poster, focused on the impressive overall survival results from their groundbreaking Phase 2 trial of Bria-IMT™ combined with immune checkpoint inhibitors (CPI) in patients suffering from metastatic breast cancer.
Showcasing Innovative Therapeutic Strategies
William V. Williams, MD, President & CEO of BriaCell, expressed the company's dedication to advancing therapeutic options that have the potential to enhance the lives of cancer patients. He remarked, “Our significant presence at this prestigious symposium underscores the extensive research and clinical development initiatives we are undertaking at BriaCell. This is a pivotal moment to connect our findings with leading experts in the cancer care community, all pursuing improved outcomes for patients.”
Spotlight on Survival Data
Among the presentations, the spotlight poster (Abstract Number: SESS-1071) titled “Overall Survival Results of Bria-IMT Allogenic Whole Cell-Based Cancer Vaccine”, will be presented on December 11, showcasing crucial results from their innovative treatments. Attendees will gain insight into the promising data indicating improved overall survival rates among participants in clinical trials.
Other Key Presentations to Note
BriaCell will also present additional noteworthy studies:
- Abstract Number: SESS-1431
Title: Identification of Antigenic Determinants in SV-BR-1 Derived Cellular Breast Cancer Vaccines - Abstract Number: SESS-2217
Title: PD-L1 Upregulation in Circulating Tumor Associated Cells Predicts for Clinical Outcomes - Abstract Number: SESS-1068
Title: ASTRO-VAC CNS: Bria-IMT in Management of Tumor Agnostic Metastatic CNS Lesions - Abstract Number: SESS-1069
Title: Bria-IMT CD8+ Tumor Infiltrating Lymphocytes Turn “Cold” Tumor “Hot” in Metastatic Breast Cancer
Engaging with the Oncology Community
BriaCell is committed to sharing insights from its studies not just to showcase its accomplishments but to foster collaboration in the oncology field. These posters will also serve as a valuable resource for clinicians and researchers looking to understand the implications of Bria-IMT and how it may enhance treatment pathways for patients battling metastatic breast cancer.
About BriaCell Therapeutics Corp.
BriaCell operates at the forefront of clinical-stage biotechnology, focusing on developing novel immunotherapies that aim to revolutionize cancer care. Through their dedicated research efforts, the organization is paving the way for groundbreaking therapies that can significantly improve patient care.
Frequently Asked Questions
What major event is BriaCell participating in?
BriaCell will be presenting five posters, including a notable spotlight poster, at the San Antonio Breast Cancer Symposium.
What does the spotlight poster focus on?
The spotlight poster focuses on overall survival results from Bria-IMT, a whole cell-based cancer vaccine.
What is Bria-IMT?
Bria-IMT is an allogenic cancer vaccine developed by BriaCell intended to treat various types of cancer, particularly metastatic breast cancer.
Who is the CEO of BriaCell?
William V. Williams, MD, serves as the President & CEO of BriaCell Therapeutics Corp.
How can I learn more about BriaCell's research?
Additional information about BriaCell’s research and findings can be accessed through their official website.